The Journal of Allergy and Clinical Immunology
Volume 125, Issue 1 , Pages 39-49 , January 2010

Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis

  • Patrick M. Schlievert, PhD

      Affiliations

    • Department of Microbiology, University of Minnesota Medical School, Minneapolis, Minn
    • Corresponding Author InformationReprint requests: Patrick M. Schlievert, PhD, Department of Microbiology, Medical School, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455.
    • ,
  • Kristi L. Strandberg, PhD

      Affiliations

    • Department of Microbiology, University of Minnesota Medical School, Minneapolis, Minn
    • ,
  • Ying-Chi Lin, MS

      Affiliations

    • Department of Experimental and Clinical Pharmacology, College of Pharmacy, Minneapolis, Minn
    • ,
  • Marnie L. Peterson, PharmD, PhD

      Affiliations

    • Department of Experimental and Clinical Pharmacology, College of Pharmacy, Minneapolis, Minn
    • ,
  • Donald Y.M. Leung, MD, PhD

      Affiliations

    • Department of Pediatrics, National Jewish Health, Denver, Colo

Received 27 August 2009 ,Revised 23 October 2009 ,Accepted 26 October 2009.

References 

  1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520–532
  2. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev. 2004;17:218–234
  3. O'Gara JP. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol Lett. 2007;270:179–188
  4. Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 1998;6:484–488
  5. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev. 2000;13:16–34
  6. Ladhani S. Recent developments in staphylococcal scalded skin syndrome. Clin Microbiol Infect. 2001;7:301–307
  7. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol. 2001;55:77–104
  8. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–1771
  9. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–1347
  10. Schlievert PM. Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect Immun. 1982;36:123–128
  11. Watson DW. Host-parasite factors in group A streptococcal infections: pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins. J Exp Med. 1960;111:255–284
  12. Bergdoll MS. Monkey feeding test for staphylococcal enterotoxin. Methods Enzymol. 1988;165:324–333
  13. Barsumian EL, Schlievert PM, Watson DW. Nonspecific and specific immunological mitogenicity by group A streptococcal pyrogenic exotoxins. Infect Immun. 1978;22:681–688
  14. Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis. 1981;143:509–516
  15. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990;248:705–711
  16. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 1993;54:99–166
  17. Li H, Llera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. Annu Rev Immunol. 1999;17:435–466
  18. Schlievert PM, Jablonski LM, Roggiani M, Sadler I, Callantine S, Mitchell DT, et al. Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals. Infect Immun. 2000;68:3630–3634
  19. Hovde CJ, Marr JC, Hoffmann ML, Hackett SP, Chi YI, Crum KK, et al. Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1. Mol Microbiol. 1994;13:897–909
  20. Peterson M, Ault K, Kremer MJ, Klingelhutz AJ, Davis CC, Squier CA, et al. Innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin-1. Infect Immun. 2005;73:2164–2174
  21. Brosnahan AJ, Mantz MJ, Squier CA, Peterson ML, Schlievert PM. Cytolysins augment superantigen penetration of stratified mucosa. J Immunol. 2009;182:2364–2373
  22. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic- shock-syndrome Staphylococcus aureus isolates. Lancet. 1981;1:1017–1021
  23. Crass BA, Bergdoll MS. Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome. J Clin Microbiol. 1986;23:1138–1139
  24. Schlievert PM. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet. 1986;1:1149–1150
  25. Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol. 2004;42:2875–2876
  26. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, et al. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol. 1997;15:1994–2007
  27. Schlievert PM, Case LC, Strandberg KL, Abrams BB, Leung DY. Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis. Clin Infect Dis. 2008;46:1562–1567
  28. Bartlett AH, Foster TJ, Hayashida A, Park PW. Alpha-toxin facilitates the generation of CXC chemokine gradients and stimulates neutrophil homing in Staphylococcus aureus pneumonia. J Infect Dis. 2008;198:1529–1535
  29. Konig B, Prevost G, Piemont Y, Konig W. Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis. 1995;171:607–613
  30. Dragneva Y, Anuradha CD, Valeva A, Hoffmann A, Bhakdi S, Husmann M. Subcytocidal attack by staphylococcal alpha-toxin activates NF-kappaB and induces interleukin-8 production. Infect Immun. 2001;69:2630–2635
  31. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, et al. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One. 2008;3:e3198
  32. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis. 2008;198:1166–1170
  33. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J Infect Dis. 2006;194:1761–1770
  34. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med. 2007;13:1405–1406
  35. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med. 2008;205:287–294
  36. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med. 2007;13:1510–1514
  37. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315:1130–1133
  38. Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect. 2009;15:156–164
  39. Hongo I, Baba T, Oishi K, Morimoto Y, Ito T, Hiramatsu K. Phenol-soluble modulin alpha3 enhances the human neutrophil lysis mediated by Panton-Valentine leukocidin. J Infect Dis. 2009;200:715–723
  40. Schlievert PM. Cytolysins, superantigens, and pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. J Infect Dis. 2009;200:676–678
  41. Davis CC, Kremer MJ, Schlievert PM, Squier CA. Penetration of toxic shock syndrome toxin-1 across porcine vaginal mucosa ex vivo: permeability characteristics, toxin distribution, and tissue damage. Am J Obstet Gynecol. 2003;189:1785–1791
  42. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997;10:505–520
  43. Monti G, Tonetto P, Mostert M, Oggero R. Staphylococcus aureus skin colonization in infants with atopic dermatitis. Dermatology. 1996;193:83–87
  44. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974;90:525–530
  45. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2008;122:261–266
  46. O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2008;122:689–693
  47. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol. 2003;48:1429–1449
  48. Pragman AA, Schlievert PM. Virulence regulation in Staphylococcus aureus: the need for in vivo analysis of virulence factor regulation. FEMS Immunol Med Microbiol. 2004;42:147–154
  49. Yarwood JM, Schlievert PM. Quorum sensing in Staphylococcus infections. J Clin Invest. 2003;112:1620–1625
  50. Schlievert PM, Case LC, Nemeth KA, Davis CC, Sun Y, Qin W, et al. Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. Biochemistry. 2007;46:14349–14358
  51. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239–244
  52. Schlievert PM. Chitosan malate inhibits growth and exotoxin production of toxic shock syndrome-inducing Staphylococcus aureus strains and group A streptococci. Antimicrob Agents Chemother. 2007;51:3056–3062
  53. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710–720
  54. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol. 1993;11:105–128
  55. Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol. 2006;118:40–43
  56. Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol. 2006;118:178–189
  57. McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118:202–208
  58. Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 1993;92:1374–1380
  59. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol. 2000;105:782–787
  60. Betley MJ, Lofdahl S, Kreiswirth BN, Bergdoll MS, Novick RP. Staphylococcal enterotoxin A gene is associated with a variable genetic element. Proc Natl Acad Sci U S A. 1984;81:5179–5183
  61. Pragman AA, Herron-Olson L, Case LC, Vetter SM, Henke EE, Kapur V, et al. Sequence analysis of the Staphylococcus aureus srrAB loci reveals that truncation of srrA affects growth and virulence factor expression. J Bacteriol. 2007;189:7515–7519
  62. Pragman AA, Yarwood JM, Tripp TJ, Schlievert PM. Characterization of virulence factor regulation by SrrAB, a two-component system in Staphylococcus aureus. J Bacteriol. 2004;186:2430–2438
  63. Yarwood JM, McCormick JK, Schlievert PM. Identification of a novel two-component regulatory system that acts in global regulation of virulence factors of Staphylococcus aureus. J Bacteriol. 2001;183:1113–1123
  64. Schlievert PM, Blomster DA. Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. J Infect Dis. 1983;147:236–242
  65. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279:593–598
  66. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus—Minnesota and North Dakota, 1997-1999. JAMA. 1999;282:1123–1125
  67. Dufour P, Gillet Y, Bes M, Lina G, Vandenesch F, Floret D, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis. 2002;35:819–824
  68. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003;9:978–984
  69. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:196–203
  70. Ito T, Kuwahara K, Hiramatsu K. Staphylococcal cassette chromosome mec(SCC mec) analysis of MRSA. Methods Mol Biol. 2007;391:87–102
  71. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290:2976–2984
  72. Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem. 2004;68:981–1003
  73. Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 2008;16:361–369
  74. Huseby M, Shi K, Brown CK, Digre J, Mengistu F, Seo KS, et al. Structure and biological activities of beta toxin from Staphylococcus aureus. J Bacteriol. 2007;189:8719–8726
  75. Gouaux JE, Braha O, Hobaugh MR, Song L, Cheley S, Shustak C, et al. Subunit stoichiometry of staphylococcal alpha-hemolysin in crystals and on membranes: a heptameric transmembrane pore. Proc Natl Acad Sci U S A. 1994;91:12828–12831
  76. Bergdoll MS, Schlievert PM. Toxic-shock syndrome toxin. Lancet. 1984;ii:691
  77. Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 1980;303:1429–1435
  78. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980;303:1436–1442
  79. Todd JK, Kapral FA, Fishaut M, Welch TR. Toxic shock syndrome associated with phage group 1 staphylococci. Lancet. 1978;2:1116–1118
  80. Parsonnet J. Case definition of staphylococcal TSS: a proposed revision incorporating laboratory findings. International Congress and Symposium Series. 1998;229:15
  81. Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, Broome CV. Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med. 1982;96:871–874
  82. Brosnahan AJ, Schaefers MM, Amundson WH, Mantz MJ, Squier CA, Peterson ML, et al. Novel toxic shock syndrome toxin-1 amino acids required for biological activity. Biochemistry. 2008;47:12995–13003
  83. Lee PK, Vercellotti GM, Deringer JR, Schlievert PM. Effects of staphylococcal toxic shock syndrome toxin 1 on aortic endothelial cells. J Infect Dis. 1991;164:711–719
  84. Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep. 2003;52:992–996
  85. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148:249–257
  86. Altemeier WA, Lewis S, Schlievert PM, Bjornson HS. Studies of the staphylococcal causation of toxic shock syndrome. Surg Gynecol Obstet. 1981;153:481–485
  87. Altemeier WA, Lewis SA, Bjornson HS, Staneck JL, Schlievert PM. Staphylococcus in toxic shock syndrome and other surgical infections: development of new bacteriophages. Arch Surg. 1983;118:281–284
  88. Altemeier WA, Lewis SA, Schlievert PM, Bergdoll MS, Bjornson HS, Staneck JL, et al. Staphylococcus aureus associated with toxic shock syndrome: phage typing and toxin capability testing. Ann Intern Med. 1982;96:978–982
  89. Assimacopoulos AP, Strandberg KL, Rotschafer JH, Schlievert PM. Extreme pyrexia and rapid death due to Staphylococcus aureus infection: analysis of 2 cases. Clin Infect Dis. 2009;48:612–614
  90. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet. 2006;367:731–739
  91. Schlievert PM, Osterholm MT, Kelly JA, Nishimura RD. Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome. Ann Intern Med. 1982;96:937–940
  92. O'Reilly M, Kreiswirth B, Foster TJ. Cryptic alpha-toxin gene in toxic shock syndrome and septicaemia strains of Staphylococcus aureus. Mol Microbiol. 1990;4:1947–1955
  93. MacDonald KL, Osterholm MT, Hedberg CW, Schrock CG, Peterson GF, Jentzen JM, et al. Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA. 1987;257:1053–1058
  94. Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med. 2005;202:209–215
  95. Fields BA, Malchiodi EL, Li H, Ysern X, Stauffacher CV, Schlievert PM, et al. Crystal structure of a T-cell receptor beta-chain complexed with a superantigen. Nature. 1996;384:188–192
  96. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994;368:711–718
  97. Li H, Llera A, Tsuchiya D, Leder L, Ysern X, Schlievert PM, et al. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity. 1998;9:807–816

 Supported by National Institutes of Health grants R01s AI74283, AI73366, and AR41256; U54-AI57153 (Great Lakes Regional Center of Excellence in Biodefense and Emerging Infectious Diseases, where P.M.S. is a member); and contract N01 AI40029 to D.Y.M.L.

 Disclosure of potential conflict of interest: P. M. Schlievert receives research support from the NIH and has provided legal consultation/expert witness testimony in cases related to streptococcal toxic shock syndrome. M. L. Peterson receives research support from the NIH and 3M. D. Y. M. Leung receives research support from the NIH/NIAID, the NIH/NIAMS, and Novartis Pharmaceuticals. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01605-4

doi: 10.1016/j.jaci.2009.10.039

The Journal of Allergy and Clinical Immunology
Volume 125, Issue 1 , Pages 39-49 , January 2010

Article Tools

* Image Usage & Resolution